The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.
Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.
Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.
AstraZeneca Plc said Ironwood Pharmaceuticals Inc. would buy the U.S. marketing rights for its newly approved gout drug for up to $265 million.
Addition of Biologic KRYSTEXXA® (pegloticase) Expands and Diversifies Horizon’s Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately Accretive to Adjusted EBITDA in 2016; Conference Call Today at 8 a.m. ET to Discuss Transaction DUBLIN, IRELAND–(Marketwired – Dec 11, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on […]
AstraZeneca’s keenly awaited cancer immunotherapy drug durvalumab may not get to market as quickly as first hoped but the company said on Thursday it was more confident than ever in its oncology development pipeline. The British drugmaker is running a lung cancer trial known as ATLANTIC that is due to produce results by the […]
An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc’s gout drug. All 10 who backed the drug, lesinurad, qualified their vote by urging the FDA to ask AstraZeneca for studies after the drug’s launch to gauge its long-term effectiveness and safety. Gout […]
Staff reviewers of the U.S. Food and Drug Administration have raised questions about the safety of AstraZeneca Plc’s gout treatment. Reviewers pointed to higher death rates, cardiovascular issues and kidney-related side effects in patients who took the drug, lesinurad, a preliminary review published on Wednesday showed. Industry analysts forecast annual sales of the drug to […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca (NYSE: AZN) today presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, results of its Phase III double-blind, multicenter, placebo-controlled trial CRYSTAL, investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with the xanthine oxidase inhibitor (XOI) febuxostat. The results demonstrated […]